Young Adult and Parent Willingness to Pay for Meningococcal Serogroup B Vaccination
- PMID: 39139368
- PMCID: PMC11320402
- DOI: 10.1177/23814683241264280
Young Adult and Parent Willingness to Pay for Meningococcal Serogroup B Vaccination
Abstract
Introduction. Serogroup B (MenB) is the leading cause of invasive meningococcal disease among adolescents and young adults in the United States. The US Advisory Committee on Immunization Practices (ACIP) recommends MenB vaccination based on shared clinical decision making between patients and providers. However, suboptimal understanding of these recommendations could contribute to low vaccination awareness and coverage. Understanding young adult and parent expectations of their health care providers (HCPs) and the value they place on vaccine information could help inform a consistent approach to HCP MenB vaccination discussions and recommendations. Methods. Data collected via a discrete-choice experiment online survey were used to evaluate preferences and willingness to pay regarding MenB vaccination among US parents and young adults in 2019. Results. Of 2,388 respondents with valid data, 1,185 were parents of children aged 12 to 25 y, and 1,203 were young adults aged 18 to 25 y. Approximately 70% of parents and young adults indicated that they would react negatively if their HCP chose not to initiate a discussion with them about MenB vaccines. Neither parents nor young adults were willing to pay for additional time for MenB vaccine discussions with their HCP but were willing to pay an average of $416 and $282, respectively, for the vaccine. For parents and young adults, greater willingness to pay was associated with a provaccination attitude and the opinion that the HCP has a moral obligation to discuss the MenB vaccine with them. Conclusion. Both parents and young adults felt their HCP is responsible for initiating a discussion about MenB vaccination and disease risk and were willing to pay for the vaccine. These findings should help inform ACIP recommendations for meningococcal vaccination.
Highlights: ACIP recommends shared clinical decision making for MenB vaccination.Data were collected from young adults and parents of adolescents by online survey.We measured values and consultation preferences on MenB disease and vaccination.Young adults/parents strongly preferred doctor-initiated MenB vaccine discussion.Respondents were willing to pay for a MenB vaccine.
Keywords: contingent valuation method; meningococcal disease; serogroup B; shared clinical decision making; vaccines; willingness to pay.
© The Author(s) 2024.
Conflict of interest statement
The work was presented at IDWeek 2020, SAHM 2020. The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: LH is a Pfizer employee and may hold stock options. AS is currently employed by Orbital Therapeutics; he was a Pfizer employee at the time of manuscript development and may hold stock options. AF reports Pfizer research support for consulting services. DW has no conflicts to report. RJ reports Pfizer research support to Duke University. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Pfizer Inc. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report.
Figures



Similar articles
-
Exploring meningococcal serogroup B vaccination conversations under shared clinical decision-making in the US.Curr Med Res Opin. 2024 Jul;40(7):1253-1263. doi: 10.1080/03007995.2024.2362924. Epub 2024 Jun 14. Curr Med Res Opin. 2024. PMID: 38860982
-
Awareness, attitudes, and practices on meningococcal serogroup B vaccination in the United States among parents of older adolescents and among young adults.Curr Med Res Opin. 2024 Jan;40(1):125-140. doi: 10.1080/03007995.2023.2285366. Epub 2024 Jan 3. Curr Med Res Opin. 2024. Update in: Curr Med Res Opin. 2024 May 6:1-4. doi: 10.1080/03007995.2024.2307342. PMID: 38032143 Updated.
-
Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.BMC Public Health. 2020 Jul 14;20(1):1109. doi: 10.1186/s12889-020-09181-8. BMC Public Health. 2020. PMID: 32664872 Free PMC article.
-
Implementation Experience With Meningococcal Serogroup B Vaccines in the United States: Impact of a Nonroutine Recommendation.Pediatr Infect Dis J. 2021 Mar 1;40(3):269-275. doi: 10.1097/INF.0000000000003033. Pediatr Infect Dis J. 2021. PMID: 33565815 Review.
-
A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.J Clin Pharm Ther. 2020 Apr;45(2):270-281. doi: 10.1111/jcpt.13083. Epub 2019 Dec 9. J Clin Pharm Ther. 2020. PMID: 31820483 Review.
References
-
- World Health Organization. Meningococcal meningitis. 2018. Available from: http://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis. [Accessed 3 October, 2020].
LinkOut - more resources
Full Text Sources
Miscellaneous